Opinion: The FDA needs to apply its Covid-19 flexibility to pediatric cancer
One of the few bright spots in the Covid-19 pandemic has been the swift development of therapies and vaccines that — beyond all odds — made it to patients in mere months versus years. The government, specifically the Food and Drug Administration, has played an essential role, flexing to expedite activities and prioritizing speed without sacrificing safety. I applaud their efforts and hope they won’t stop there.
As a mother who watched her 9-year-old son, Zach, die from aggressive leukemia following four years of harrowing therapy and three bone marrow transplants, I urge the government and the biopharma industry to apply a similar spirit of innovation and resolve in tackling another critical challenge: childhood cancer.
